Viehbacher loses bid to save job, ousted as CEO of Sanofi
Jeffrey Clark - Posted: 10/29/2014
Sanofi fired its CEO Chris Viehbacher on Wednesday.  The move comes just days after it was learned that Viehbacher was fighting to keep his role at the French drug maker. The reason?  An uncommunicative management style, Chairman Serge Weinberg said.[...]
Amgen not splitting up, cutting workforce even deeper
Jeffrey Clark - Posted: 10/29/2014
One of the life sciences biggest companies is getting smaller. Amgen, this week, Monday said that it will cut an additional 5% of its workforce in addition to the 2,900 positions it had already projected it will lose as it restructures. The changes, [...]
Sanofi CEO Viehbacher makes case to save his job
Jeffrey Clark - Posted: 10/28/2014
Sanofi CEO Chris Viehbacher, is all of a sudden, fighting for his professional career. The company has struggled of late with tensions rising between the CEO and the Board of Directors. First came Sanofis plan to divest $8B in drugs, with board consu[...]
Valeant CEO believes Allergan misinforming the public
Jeffrey Clark - Posted: 10/22/2014
Valeant CEO Mike Pearson on the CNBC set talking about Valeant, Allergan and the struggle to make a deal. In this interview, Pearson alleges that Allergan made false and inflammatory statements over the course of the past few months.
Valeant CEO talks company performance as Allergan showdown looms
Jeffrey Clark - Posted: 10/22/2014
Michael Pearson, Valeant Pharmaceuticals CEO, breaks down the companys quarterly numbers and provides an outlook on future growth as the Allergan merger battle continues.
AbbVie/Shire deal officially off after US thwarts inversion benefits
Jeffrey Clark - Posted: 10/21/2014
For the first time, a company has cancelled its planned merger with a foreign partner for reasons related to tax inversion. After rationalizing its intent by stating obvious synergies between the two companies, AbbVie officials have now announced tha[...]
A challenge for a pharmaceutical company called ISIS
Jeffrey Clark - Posted: 10/17/2014
The editors at CNN asked a very poignant question today, partially relevant to the life sciences industry:  What if your business is called ISIS? Most in the life sciences are aware of ISIS Pharmaceuticals, the drug development firm in Carlsbad, CA l[...]
AbbVie reconsiders Shire deal amid US changes to tax inversions
Jeffrey Clark - Posted: 10/15/2014
Medtronic reaffirmed its commitment last week to acquire Covidien on the heels of the US federal government making it more difficult for companies to benefit from so-called tax inversion deals.  Medtronic believes there is enough strategic synergy to[...]
Chinese firm enters race to develop Ebola treatment
Jeffrey Clark - Posted: 10/14/2014
Ebola is now spreading beyond its stronghold in western Africa to more developed countries.  And, the world is reacting and responding with contingency plans, treatments and potential cures in fast track development. One Chinese drugmaker with close [...]
Becton Dickinson acquires Carefusion for $12B
Jeffrey Clark - Posted: 10/13/2014
Becton, Dickinson & Co. has agreed to buy CareFusion for $12.2 billion in a deal that could be finalized during the first half of next year.  Recent research and development activities at the two firms have focused on tools used to minimize patient-s[...]
Can Actavis save Allergan from Valeant? And, the Love Quadrilateral?
Jeffrey Clark - Posted: 10/8/2014
Will Actavis ride in as a white knight for Allergan? After being rebuffed by Allergan with a tepid offer last month, Actavis has returned with a more convincing strategy. Actavis is selling the promise of less cost cutting to fund the transaction, wh[...]
Medtronic to finance Covidien deal, avoid appearance of inversion deal
Jeffrey Clark - Posted: 10/7/2014
Medtronic has announced that it will not fund its acquisition of Covidien using foreign cash as it originally planned, but rather will use external financing amounting to $16 billion.   The announcement follows a recent move by the Treasury Departmen[...]
Ebola reaches US, life sciences industry responds
Jeffrey Clark - Posted: 10/2/2014
Ebola has found its way to the United States. The first confirmed US case of Ebola was announced in Dallas this week, from a man who traveled from Liberia (center of the Ebola outbreak in Africa) to Texas. The announcement has health officials scramb[...]
J&J acquires Alios to compete with Gilead and Sovaldi
Jeffrey Clark - Posted: 9/30/2014
Seeing the cash register ring in hepatitis C for Gilead, Johnson & Johnson is making its own move with a $1.75 billion for Alios Biopharma and its development pipeline.   Alios operates in the category of nucleotide analogs (nucs), oral[...]
House votes to repeal medical device tax. But, wait?
Jeffrey Clark - Posted: 9/29/2014
The Republican-controlled House has twice passed legislation to scrap the tax, including a recent measure that would have also delayed implementation of the health law by a year. In the Senate, 33 Democrats and Maine Independent Angus King voted earl[...]
Astellas driving to become Employer of Choice in life sciences
Jeffrey Clark - Posted: 9/25/2014
Ken Jones, CEO of Astellas Pharmaceuticals EMEA, talks about the company's leadership journey as it attempts to evolve as an Employer of Choice across the life sciences industry.
US Treasury clamps down on inversion, big life sciences deals in question
Jeffrey Clark - Posted: 9/23/2014
The U.S. Treasury Department announced steps that will make it harder for US companies to move their addresses outside the country to reduce their taxes, clamping down on the practice known as inversions. The life sciences industry has been at the fo[...]
Salix and Actavis play key roles in Allergan/Valeant saga
Jeffrey Clark - Posted: 9/23/2014
With a looming December 18th special meeting, Allergan and Valeant are playing the chess board. If you believe the press, Actavis recently made a friendly $50B bid for the company which was rejected. And, Allergan is now closing in on its own $10B ac[...]
GSK corruption charges settled in China, suspended jail sentence
Jeffrey Clark - Posted: 9/19/2014
The GSK corruption case in China has come to a conclusion, after a trial that was held in secret. The result is a $489M fine and a suspended sentence for Mark Reilly, GSKs top executive in China.  Reports suggest Reilly will be given a three year sus[...]
What Scotland vote means for life sciences?
Jeffrey Clark - Posted: 9/19/2014
With this mornings announcement that Scotland has rejected a referendum vote for independence, PharmaPhorum has published an article on the immediate and long term positive ramifications for the life sciences industry. Scotland will remain part of th[...]
Israeli robotics company soars with success of ReWalk
Jeffrey Clark - Posted: 9/18/2014
On CNBC this morning, ReWalk CEO Larry Jasinski discusses just how big the market for wearable robotic exoskeleton devices could get. ReWalks have been marketed in Europe since 2012 and received Food and Drug Administration approval for U.S. use in J[...]
Op-ed: High priced drugs are often worth the expense
Jeffrey Clark - Posted: 9/18/2014
Gilead Sciences Sovaldi for hepatitis C is the most successful drug product launch of all time.  It is also an incredibly expensive one-time treatment. And, while the costs of such drugs can hit health care budgets hard all at once, their value to pa[...]
Star Trek meets medical devices with tricorder contest by Qualcomm
Jeffrey Clark - Posted: 9/15/2014
Welcome to the intersection of science fiction and the medical device industry. Qualcomm is sponsoring the Tricorder X contest to create an affordable, handheld device that consumers can use to diagnose their medical conditions at home. The contest’s[...]
Google, Apple, others frustrated by regulatory hurdles for new tech
Jeffrey Clark - Posted: 9/12/2014
This is a fantastic article from the Associated Press on the growing pains felt by Silicon Valley entrepreneurs venturing into the healthcare industry.  Unlike technology where companies can launch a product unabated, companies like Google, Apple and[...]
Third weight loss treatment in past two years approved by FDA
Jeffrey Clark - Posted: 9/11/2014
For the third time in about two years, the Food and Drug Administration has approved a new weight-loss pill.  On Wednesday, FDA released approval to Orexigen Therapeutics oral drug Contrave, for use in chronic weight management along with a low-calor[...]
Becton Dickinson acquires[...]
Becton, Dickinson & Co. has agreed to buy CareFusion for $12.2 billion in a deal that could be final[...]
Ebola reaches US, life sc[...]
Ebola has found its way to the United States. The first confirmed US case of Ebola was announced in [...]
Astellas driving to becom[...]
Ken Jones, CEO of Astellas Pharmaceuticals EMEA, talks about the company’s leadership journey as it [...]
US Treasury clamps down o[...]
The U.S. Treasury Department announced steps that will make it harder for US companies to move their[...]
Israeli robotics company [...]
On CNBC this morning, ReWalk CEO Larry Jasinski discusses just how big the market for wearable robot[...]